HER2 Breast Cancer

The 2017 Miami Breast Cancer Conference, to be held March 9 to 12 at the Fontainebleau Miami Beach, welcomes an expanded group of program chairs, and a newly established curriculum committee made up of a multidisciplinary group of breast cancer specialists.

An attempt to strengthen neoadjuvant treatment of patients with locally advanced HR-positive and HER2-positive breast cancer by adding estrogen deprivation therapy to a standard regimen failed to significantly improve response rates.

Higher levels of tumor-infiltrating lymphocytes (TILs) were associated with improvements in overall survival (OS) for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta).

Debu Tripathy, MD, chair, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the potential for immunotherapy in the treatment of HER2+ breast cancer.

An expert panel, consisting of the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology issued comprehensive, evidence-based guidelines for clinicians and pathologists regarding the testing of HER2 status for patients with gastroesophageal adenocarcinoma. 

In an interview with <em>Targeted Oncology</em>, Frankie Holmes, MD, discusses HER2-directed therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta).

New findings from a study suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer. Instead, gene networks&mdash; specifically those involving PI3 kinase &mdash;may provide a clearer picture of patient outcomes.

Though some clinicians may characterize the treatment landscape of HER2-positive breast cancer as overcrowded, Mark Pegram, MD, firmly believes that there is still much to learn in this space.

According to phase I data presented at the 2016 ESMO Congress, a&nbsp;novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the future of HER2+ breast cancer treatment.

ASCO-CAP recently released new guidelines for the use of FISH testing for HER2 in breast cancer, due to discrepancies in HER2-testing results.

Results from the KRISTINE^&nbsp;and NSABP B-41&nbsp;trials provided the latest data on the use of pertuzumab, trastuzumab, ado-trastuzumab emtansine, and lapatinib for the neoadjuvant treatment of patients with HER2-positive breast cancer.

Melanie Royce, MD, details recent studies into&nbsp;hormone receptor-positive (HR+) and HER2-advanced breast cancer treatment.

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center, and Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, discusses the potential role of immunotherapy in the management of breast cancer.

William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.

Chau T. Dang, MD&nbsp;discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.

A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA

<div>The developer of neratinib, Puma Biotechnology, has announced the European Medicines Agency (EMA) has validated the marketing authorization application for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab (Herceptin).</div>

Breast cancer has traditionally not been viewed as immunogenic. There is now a growing body of evidence that immune infiltration has a prognostic role in al breast cancer subtypes, and predicts improved clinical outcome in triple-negative and human epidermal growth factor receptor 2-positive tumors.

For patients with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status, ASCO&#39;s February 2016 release of their evidence-based recommendations helped define appropriate use of biomarker assay results in guiding adjuvant treatment decisions.

A number of small changes that were specific to neoadjuvant and adjuvant therapies were made to the NCCN breast cancer guidelines, additionally, the recommended treatments for patients with ER-positive disease were also modified.

In patients with HER2-positive early breast cancer, data from a phase III trial has shown a significantly higher pathological complete response (pCR) rate with neoadjuvant docetaxel plus carboplatin plus trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.

Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.

Following a series of meetings with the FDA, Puma Biotechnology announced that it plans to delay the submission of a new drug application (NDA) until mid-2016 for neratinib.

Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the future of immunotherapies and anti-HER2 drugs in the treatment paradigm for HER2-positive breast cancer.